ENA 100 (Idhifa 100 mg)
Generic Name: enasidenib
Pill with imprint ENA 100 is Yellow, Capsule-shape and has been identified as Idhifa 100 mg. It is supplied by Celgene Corporation.
Idhifa is used in the treatment of acute myeloid leukemia and belongs to the drug class miscellaneous antineoplastics. Idhifa 100 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for ENA 100
Idhifa
- Generic Name
- enasidenib
- Imprint
- ENA 100
- Strength
- 100 mg
- Color
- Yellow
- Size
- 15.00 mm
- Shape
- Capsule-shape
- Availability
- Prescription only
- Drug Class
- Miscellaneous antineoplastics
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Celgene Corporation
- National Drug Code (NDC)
- 59572-0710
- Inactive Ingredients
-
microcrystalline cellulose,
sodium starch glycolate type A potato,
sodium lauryl sulfate,
hypromellose acetate succinate 06081224 (3 mm2/s),
silicon dioxide,
magnesium stearate,
polyvinyl alcohol,
titanium dioxide,
polyethylene glycol,
magnesium silicate,
ferric oxide yellow
Note: Inactive ingredients may vary.
More about Idhifa (enasidenib)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: miscellaneous antineoplastics
- FDA Alerts (1)
- FDA Approval History
Consumer resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.